drugset / Trial / NCT03873727
Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients.
Phase 2
Completed
39 enrolled
Assistance Publique - Hôpitaux de Paris
CIC 1417 Cochin-Pasteur · collabEUCLID Clinical Trial Platform · collabI-REIVAC Innovative Clinical Research Network In Vaccinology · collabURC-CIC Paris Descartes Necker Cochin · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
This research is a multi-center French randomized and double blind phase IIb clinical trial evaluating 2 revaccination strategies against pneumococcal infections among splenectomised patients. The main objective is to evaluate at M13 the immunological response of 2 pneumococcal revaccination strategies (combined revaccination by a boost dose of PCV13 following 12 months later by PPS23, versus PPS23 alone) in splenectomised adults.
Timeline
- Start
- 2019-08-27
- Primary completion
- 2022-05-24
- Completion
- 2024-05-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Prevnar 13 | Vaccine | — | — |
| Background | Pneumovax 23 | Vaccine | — | — |
Indications
No indication recorded.